Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized double-blind placebo-controlled Phase 2 study of inhaled CSJ117 in severe uncontrolled asthma
2019-004905-29Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ecleralimab in asthma (6 arms), sponsored by Novartis. Primary endpoint: Average change from baseline in pre-dose FEV1 at Week 8 and Week 12. Started Sep 2020; status: completed.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-004905-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004905-29.